Ublituximab Treatment is Associated with a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results from the Ultimate I and Ultimate II Phase 3 Studies of Ublituximab vs Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Download

Drug Category : Array

Conference Category : Array

Lead Author : Alvarez E, et al.

Published Date : 03/04/2022

Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2022/04/Alvarez_NEDA_AAN_2022.pdf

Download Text : Download

Popup Confirmation? :

site-sidebar-layout : default

ast-site-content-layout : default

site-content-style : default

site-sidebar-style : default

theme-transparent-header-meta : default

stick-header-meta : default

astra-migrate-meta-layouts : set